Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.62 |
| ▸ | THRB | P10828 | 1/20 | 0.62 |
| ▸ | MTOR | P42345 | 1/20 | 0.62 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.62 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.62 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.62 |
| ▸ | NT5E | P21589 | 1/20 | 0.51 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.46 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.46 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.44 |
| ▸ | ST6GAL1 | P15907 | 1/20 | 0.42 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.42 |
| ▸ | ALB | P02768 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.42 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3345914 | 0.99 | LMNA (0.60) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL18740734 | 0.81 | LMNA (0.58) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL30989748 | 0.80 | LMNA (0.54) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL2835710 | 0.80 | LMNA (0.69) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL10015791 | 0.79 | LMNA (0.67) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL399323 | 0.79 | LMNA (0.67) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL4879682 | 0.79 | LMNA (0.67) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL18693664 | 0.79 | LMNA (0.67) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL399324 | 0.79 | LMNA (0.67) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL11588975 | 0.78 | LMNA (0.79) | LMNATHRBMTORMDM2NCOA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2211870-A1 | CYTIDINE ANALOGS FOR TREATMENT OF MYELODYSPLASTIC SYNDROMES | CELGENE CORPORATION (US) | 2010-08-04 | — | — | EP | claimed |
| WO-2009058394-A1 | CYTIDINE ANALOGS FOR TREATMENT OF MYELODYSPLASTIC SYNDROMES | CELGENE CORPORATION (US) | 2009-05-07 | — | — | WO | claimed |
| WO-2008129530-A1 | GEMCITABINE PRODUCTION PROCESS | CHEMAGIS LTD. (IL) | 2008-10-30 | — | — | WO | claimed |
| WO-2007070804-A2 | PROCESS FOR PREPARING GEMCITABINE AND ASSOCIATED INTERMEDIATES | CHEMAGIS LTD. (IL) | 2007-06-21 | — | — | WO | claimed |
| US-20050159375-A1 | Novel oligonucleotides and related compounds | CHEMGENES CORPORATION | 2005-07-21 | — | — | US | claimed |
| EP-1485395-A2 | NUCLEOTIDE MIMICS AND THEIR PRODRUGS | Biota, Inc. (US) | 2004-12-15 | — | — | EP | claimed |
| EP-1483401-A1 | METHOD FOR SELECTING DRUG SENSITIVITY-DETERMINING FACTORS AND METHOD FOR PREDICTING DRUG SENSITIVITY USING THE SELECTED FACTORS | F.HOFFMANN-LA ROCHE AG (CH) | 2004-12-08 | — | — | EP | claimed |
| WO-2003072757-A9 | NUCLEOTIDE MIMICS AND THEIR PRODRUGS | BIOTA INC (US) | 2004-10-21 | — | — | WO | claimed |
| WO-2003076660-A1 | METHOD FOR SELECTING DRUG SENSITIVITY-DETERMINING FACTORS AND METHOD FOR PREDICTING DRUG SENSITIVITY USING THE SELECTED FACTORS | F.HOFFMANN-LA ROCHE AG (CH) | 2003-09-18 | — | — | WO | claimed |
| WO-2003072757-A2 | NUCLEOTIDE MIMICS AND THEIR PRODRUGS | BIOTA, INC. (US) | 2003-09-04 | — | — | WO | claimed |
| WO-2025096203-A1 | TARGETING A CHIMERIC RNA FOR TREATING CANCER | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2025-05-08 | — | — | WO | disclosed |
| EP-4281068-A1 | COMBINATION THERAPY SCHEDULES TO TREAT CANCER | Board of Regents, The University of Texas System (US) | 2023-11-29 | — | — | EP | disclosed |
| CN-116642991-A | Combined determination method, kit and application of antitumor drugs | 江苏豪思生物科技有限公司 | 2023-08-25 | — | — | CN | disclosed |
| CN-114404581-A | Cancer vaccine | 摩登纳特斯有限公司 | 2022-04-29 | — | — | CN | disclosed |
| EP-3908261-A1 | LIPOSOME COMPOSITION COMPRISING LIPOSOMAL PRODRUG OF MITOMYCIN C AND METHOD OF MANUFACTURE | Lipomedix Pharmaceuticals Ltd. (IL) | 2021-11-17 | — | — | EP | disclosed |
| US-5434254-A | Process for preparing 2',2'-difluoronucleosides | ELI LILLY AND COMPANY (US) | 1995-07-18 | — | — | US | disclosed |
| EP-0630905-A1 | Process for selectively isolating bêta-2'-deoxy-2',2'-difluorocytidine or its salts | ELI LILLY AND COMPANY (US) | 1994-12-28 | — | — | EP | disclosed |
| US-5223608-A | Process for and intermediates of 2',2'-difluoronucleosides | ELI LILLY AND COMPANY (US) | 1993-06-29 | — | — | US | disclosed |
| US-4965374-A | Process for and intermediates of 2',2'-difluoronucleosides | ELI LILLY AND COMPANY (US) | 1990-10-23 | — | — | US | disclosed |
| EP-0306190-A2 | Improvements in or relating to 2',2'-difluoronucleosides | ELI LILLY AND COMPANY (US) | 1989-03-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050159375-A1 | Novel oligonucleotides and related compounds | DCLRE1B, TYMP, DUT | LMNA 3478/4885THRB 2282/4885MTOR 4656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.